Menu
← Oncology Approval Tracker
FDA DECISION ·
Tafinlar + Mekinist
dabrafenib + trametinib · Novartis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For children aged one year or older with BRAF V600E-mutant low-grade glioma requiring systemic treatment. FDA also approved oral formulations for patients unable to swallow pills.
LAMPGEN ANALYSIS
Why it matters
The combination offered biomarker-directed treatment for pediatric low-grade glioma with age-appropriate administration options.
What research teams should watch
Confirm the BRAF variant, systemic-treatment need and the child's ability to use the prescribed oral formulation.
PRIMARY RECORDS